Altiratinib

Altiratinib
Altiratinib
Chemical nomenclature
IUPAC name	N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-N'-(4-(dimethylamino)phenyl)urea
Identifiers
CAS Number	123456-78-9
PubChem	12345678
ChemSpider	123456
UNII	123456789A
KEGG	D12345
ChEMBL	1234567
Chemical data
Chemical formula	C24H26N4O4
Molecular weight	434.49 g/mol

Altiratinib is a small molecule tyrosine kinase inhibitor that targets multiple receptor tyrosine kinases (RTKs) involved in cancer progression and metastasis. It is primarily being investigated for its potential use in treating various types of cancer, including glioblastoma, breast cancer, and colorectal cancer.

Mechanism of Action

Altiratinib functions by inhibiting the activity of several key RTKs, including MET, TIE2, and VEGFR2. These kinases play crucial roles in tumor growth, angiogenesis, and the metastatic spread of cancer cells. By blocking these pathways, altiratinib aims to reduce tumor proliferation and prevent the formation of new blood vessels that supply the tumor with nutrients.

MET Inhibition

The MET receptor is often overexpressed or mutated in various cancers, leading to increased tumor cell proliferation, survival, and metastasis. Altiratinib's ability to inhibit MET can disrupt these processes, potentially leading to reduced tumor growth and spread.

TIE2 Inhibition

TIE2 is a receptor involved in angiogenesis, the process by which new blood vessels form from pre-existing vessels. By inhibiting TIE2, altiratinib may help to starve tumors of their blood supply, thereby inhibiting their growth.

VEGFR2 Inhibition

VEGFR2 is another critical player in angiogenesis. Inhibition of VEGFR2 by altiratinib further contributes to its anti-angiogenic effects, complementing the inhibition of TIE2.

Clinical Development

Altiratinib is currently undergoing clinical trials to evaluate its safety and efficacy in humans. Early-phase trials have shown promise, with some patients experiencing stabilization of their disease. Ongoing studies aim to determine the optimal dosing regimen and to identify specific patient populations that may benefit the most from this treatment.

Potential Side Effects

As with many cancer therapies, altiratinib may cause side effects. Commonly reported adverse effects include fatigue, nausea, hypertension, and diarrhea. More serious side effects could include liver toxicity and cardiovascular events, necessitating careful monitoring during treatment.

Research and Future Directions

Research is ongoing to better understand the full potential of altiratinib in cancer therapy. Combination studies with other anticancer agents are being explored to enhance its therapeutic efficacy. Additionally, biomarker studies are being conducted to identify patients who are most likely to respond to altiratinib treatment.

Also see

• Tyrosine kinase inhibitor
• Cancer treatment
• Angiogenesis inhibitors
• MET receptor
• VEGFR2

Receptor Tyrosine Kinase Inhibitors

Name	Target	Indications	Notes
Imatinib	BCR-ABL	Chronic myeloid leukemia, Gastrointestinal stromal tumor	First approved RTK inhibitor
Erlotinib	EGFR	Non-small cell lung cancer, Pancreatic cancer	Used in combination with gemcitabine for pancreatic cancer
Sunitinib	VEGFR, PDGFR	Renal cell carcinoma, Gastrointestinal stromal tumor	Multi-targeted RTK inhibitor
Gefitinib	EGFR	Non-small cell lung cancer	First EGFR inhibitor approved
Sorafenib	VEGFR, RAF kinase	Hepatocellular carcinoma, Renal cell carcinoma	Also inhibits RAF kinases
Lapatinib	HER2/neu, EGFR	Breast cancer	Used in combination with capecitabine